The most recent formal update to Tadalafil’s (the active ingredient in Tadalista 5 mg) approved product information from an official regulatory source appears to be the U.S. FDA label revision dated October 2023, which is currently listed in official drug labeling databases as the latest approved version of the tadalafil product label.
This label document notes indicating that the prescribing information was updated at that time — although the label itself states it may not be the latest approved version, it’s the most recent publicly available update in the FDA database as of late 2025/early 2026.
Key point:
The last widely referenced update for tadalafil product labeling in the U.S. regulatory database is October 2023.
If you’re asking about specific safety updates for Tadalista 5 mg itself (e.g., in India or other countries), there isn’t a clearly documented, publicly posted recent regulatory update for this generic brand specifically in global safety bulletins fast indexed online — generic labels typically follow the originator drug’s approved information and are updated when major safety or indication changes occur.
For general safety variations on tadalafil generics, some authorities update labels (e.g., BPH indication changes seen in certain countries), but a precise “last update date for Tadalista 5 mg” wasn’t prominently found in major public databases.